knowledge -WSS

knowledge

author：fashion 2025-10-01 14:19:37 - browse：19

Stock exchange — Drew Angerer/Getty Images

Viking Therapeutics said Tuesday that its closely watched oral obesity drug had succeeded in an early-stage trial and that it planned to advance the medicine into the next phase of development.

The top-line results released Tuesday were only from a Phase 1 study, which primarily focuses on a drug’s safety. But Viking said that in the study, its medicine led to a roughly 3.3% placebo-adjusted average weight loss after four weeks and that it showed no safety issues.

In preview notes, analysts had said that investors would want to see between 3% and 4% placebo-adjusted weight loss. Shares of San Diego-based Viking were up more than 20% in pre-market trading Tuesday.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： As demand for Covid shots wanes, Moderna seeks its next success
Next article： What is STAT's opinion section for?

explore

WSS

Healthy food access boosts outcomes in two studies

What health policies could hitch a ride on a spending bill?

CVS, Rite Aid closures threaten to worsen pharmacy deserts

What is STAT's opinion section for?

CVS, Rite Aid closures threaten to worsen pharmacy deserts

Eli Lilly’s chief scientist on obesity drugs, gene editing, and more

entertainment

knowledge

leisure time

Supreme Court strikes down use of affirmative action

Second xenotransplant done with gene

Affirmative action in medical school literally saved lives

CommonSpirit Health keeps growing, even as it loses money

Novavax promises a turnaround & Lilly roils the obesity market

Cancer diagnosis changes perspective doctor, former hospital CEO

Novavax promises a turnaround & Lilly roils the obesity market

CVS, Rite Aid closures threaten to worsen pharmacy deserts

FDA approval of Sarepta Duchenne genetic therapy gives me hope

CDC's new outbreak response network to include Northeastern

leisure time

Ventyx halts psoriasis drug development after lackluster trial results

What is STAT's opinion section for?

Experimental asthma app from Apple and Anthem shows promise

CommonSpirit Health keeps growing, even as it loses money

Experts study whether long Covid risk adds up with each reinfection

Thermo Fisher plant for manufacturing gene therapies to expand

leisure time

explore

explore

leisure time